A Major Regulatory Reset Effective November 2026
China’s National Medical Products Administration (NMPA) has released a comprehensively revised Medical Device Good Manufacturing Practice (GMP), that will replace the 2014 framework and taking effect on November 1, 2026.
The new regulation expands expectations well beyond traditional production controls, establishing a full lifecycle quality management system (QMS) that integrates design, production, supplier management, data integrity, and post-market activities.
For many manufacturers, this is not a minor update. It is a system-level transformation.
What Has Changed: From Production Control to Lifecycle Quality
The revised GMP requires manufacturers to implement a quality system that spans:
- Design and development
- Production and process control
- Supplier and outsourced operations
- Product release and traceability
- Complaint handling and adverse events, and
- Recall and post-market monitoring.
This represents a shift toward a continuous, risk-based quality model, rather than a production-centric compliance approach.
Key Areas of Increased Expectations
Management Accountability and Organizational Structure
The regulation formalizes leadership responsibility and requires independent quality functions, defined roles for key personnel, and qualified, full-time leadership in critical positions.
Quality is no longer a supporting function; it is a governance function.
Design Controls Become Central
For the first time, design and development are treated as a fully controlled system, including design planning and documentation, verification and validation, design transfer to production, and design change control.
This elevates design from a regulatory step to a core quality subsystem.
Risk Management Across the Lifecycle
Risk management is explicitly required to span the entire product lifecycle, inform decision-making at all stages, and be continuously reviewed and updated. This creates a system where quality decisions must be risk-justified and data-supported.
Data Integrity and Digital Systems
The new GMP introduces stronger expectations for electronic records and data control, user access and permissions, change tracking and auditability, and software validation based on risk. It also encourages digital transformation, signaling a move toward more modern, data-driven operations.
Supplier and Outsourcing Control
Manufacturers must now classify suppliers based on risk, conduct audits and ongoing evaluations, establish formal quality agreements, and control outsourced production and testing. Entrusted manufacturing relationships are subject to structured oversight and shared accountability.
Production Discipline and Traceability
The regulation strengthens expectations for batch records and traceability, material balance controls, deviation and nonconformance management, and Unique Device Identification (UDI). Production systems must demonstrate control, consistency, and traceability.
Post-Market Feedback and Continuous Improvement
Manufacturers are required to implement systems for complaint handling, adverse event monitoring, product recalls, data analysis, and CAPA. Quality is no longer confined to manufacturing. It extends into real-world product performance.
Practical Impact on Manufacturers
For many companies, the challenge will not be a single requirement. It will be integration.
Where Companies May Struggle Most
Connecting Systems Across the Lifecycle
Many organizations operate in silos of design, production, quality, and post-market, but the new GMP expects these functions to operate as a single system.
Organizational Readiness
The new GMP has requirements for qualified personnel, independent quality roles, and defined personnel responsibilities. This may require organizational restructuring.
Digital and Data Systems
Companies relying on spreadsheets, legacy systems, and informal data controls will face immediate gaps.
Supplier and Outsourcing Oversight
Existing supplier relationships may lack formal agreements, risk classification, and audit structure.
Design Transfer and Change Control
Bridging development to production remains a known weak point across industry.
A Broader Shift Toward Global Alignment
While unique in structure and terminology, the revised China GMP reflects broader global trends of lifecycle quality systems, risk-based decision-making, stronger supplier oversight, data integrity and digitalization, and post-market integration. For global manufacturers, this creates both alignment opportunities and implementation challenges.
Going Forward
The transition period to November 2026 provides time, but not unlimited time. Manufacturers will need to assess current systems, identify gaps, prioritize remediation, and build integrated quality frameworks.
The key question is no longer “Are we compliant?” It is “Do our systems function as a complete, risk-based quality system?”
How MDP Can Support
Medical Devices and Pharma (MDP) is developing resources and services to support China GMP gap assessments, implementation planning, cross-regulatory alignment (China, QMSR, ISO 13485, EU MDR), training and education programs, and supplier and outsourcing quality systems.
